CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS...License and Commercialisation Agreement • April 21st, 2015 • Biotie Therapies Corp. • Pharmaceutical preparations
The Parties hereby acknowledge and agree to include this Amendment to be an integral part of the Agreement and extend, supplement, vary, change, modify and amend the Agreement as set forth herein. The change shall become effective only upon notification by Lundbeck in writing of its entering into a Co-Promotion and Distribution Agreement with Whanin Pharmaceutical Co. Ltd. regarding the distribution and sale of the Product in the Republic of Korea, referred to in Section 3 below.
TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • April 21st, 2015 • Biotie Therapies Corp. • Pharmaceutical preparations • New York
This Termination and Transition Agreement (“Termination and Transition Agreement”) is made and entered into as of August 22, 2014 (the “Termination and Transition Effective Date”) by and between Biotie Therapies Inc. (formerly Synosia Therapeutics, Inc.), a corporation organized under the laws of the State of Delaware, with its principal office at 701 Gateway Blvd, Suite 350, South San Francisco, California 94080, United States (“Biotie Inc.”); Biotie Therapies AG (formerly Synosia Therapeutics AG and successor in the merger between Biotie Therapies AG and Biotie Therapies Holding AG (formerly Synosia Therapeutics Holding AG)), a company organized under the laws of Switzerland, with its principal office at Kohlenberg 3, 4051 Basel, Switzerland (“Biotie AG” and, collectively with Biotie Inc., “Biotie”) on the one hand, and UCB Biopharma S.P.R.L., a company organized under the laws of Belgium, with its principal office at Allée de la Recherche 60, B-1070 Brussels, Belgium (“UCB”), on the
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS...License and Commercialisation Agreement • April 21st, 2015 • Biotie Therapies Corp. • Pharmaceutical preparations
The Parties hereby acknowledge and agree to include this Amendment to be an integral part of the Agreement and extend, supplement, vary, change, modify and amend the Agreement as set forth herein. The change shall become effective only upon payment of the execution fee referred to in Section 3 below.
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS...License and Commercialisation Agreement • April 21st, 2015 • Biotie Therapies Corp. • Pharmaceutical preparations
The Parties acknowledge and agree hereby to include this Amendment to be an integral part of the Agreement and extend, supplement, vary, change, modify and amend the Agreement as set forth herein. The changes shall become effective only upon payment of the execution fee referred to in Section 4 below.
BioTie Therapies Corp. Tykistökatu 6 20520 Turku FinlandBiotie Therapies Corp. • April 21st, 2015 • Pharmaceutical preparations
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS...License and Commercialisation Agreement • April 21st, 2015 • Biotie Therapies Corp. • Pharmaceutical preparations
The Parties hereby acknowledge and agree to include this Amendment to be an integral part of the Agreement and extend, supplement, vary, change, modify and amend the Agreement as set forth herein.
LICENSE AND COMMERCIALISATION AGREEMENT BETWEEN BIOTIE THERAPIES CORP. Tykistökatu 6 20520 Turku Finland (Hereinafter referred to as “BioTie”) - and - Ottiliavej 9 DK 2500 Valby Denmark (Hereinafter referred to as “Lundbeck”)Exclusive License Agreement • April 21st, 2015 • Biotie Therapies Corp. • Pharmaceutical preparations
